Limb Lengthening And Deformity Correction Surgery
2017-11-29Current approaches
The innovative treatments in development for achondroplasia are focused on the increase of growth rate and in the reduction of possible complications. The only available treatment is surgical and is known as limb lengthening surgery. Limb lengthening can help gain some proportionality and can correct health compromising deformities in the upper and lower limbs and height may or may not be increased during treatment.
TransCon CNP
2017-11-16Emergent treatments
TransCon CNP is a new molecule for achondroplasia under development by Ascendis Pharma. Its mechanism of action is similar to the one used by Vosoritide, but with a modification in a formulation that makes a big difference. Learn more about it here.
TA-46 Mechanism Of Action
2017-11-16Emergent treatments
TA-46 is a soluble form of FGFR3. This receptor that exists in chondrocytes is where is the mutation in achondroplasia is located. Phase 1 clinical trials for this molecule will start in early 2018. Learn more about how it works and how far it is in development here.
BMN-111 Mechanism of Action
2017-06-15Emergent treatments
BMN-111 is an emergent treatment for achondroplasia. It is now in a Phase III clinical trial and aims to bring a treatment to the condition. In this article you can read more on how it works, its strong suits and drawbacks.